FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nigel Stallard

Research Profile

Concepts & Ideas

Activities & Behaviors

Procedures

Living Beings

Animals, Laboratory

Disorders

Neoplasms, Experimental

Co-author Network

Publications

TOP 3
Roshini Sooriyarachchi; Patrick Kelly; Yinghui Zhou; Nigel Stallard; Helene Thygesen; Clive Bowman
Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme.
Patrick Kelly; Nigel Stallard; Yinghui Zhou; Roshini Sooriyarachchi; Clive Bowman
Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.
Claudio J Verzilli; Nigel Stallard; John C Whittaker
Bayesian graphical models for genomewide association studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nigel Stallard (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Roshini Sooriyarachchi; Patrick Kelly; Yinghui Zhou; Nigel Stallard; Helene Thygesen; Clive Bowman
Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme.
Pharmaceutical statistics 2009;8(4):287-300.
2006: Patrick Kelly; Nigel Stallard; Yinghui Zhou; Roshini Sooriyarachchi; Clive Bowman
Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.
Statistics in medicine 2006;25(18):3081-92.
2006: Claudio J Verzilli; Nigel Stallard; John C Whittaker
Bayesian graphical models for genomewide association studies.
American journal of human genetics 2006;79(1):100-12.
2005: Patrick J Kelly; Nigel Stallard; John C Whittaker
Statistical design and analysis of pharmacogenetic trials.
Statistics in medicine 2005;24(10):1495-508.
2005: Claudio J Verzilli; Nigel Stallard; John C Whittaker
Bayesian modelling of multivariate quantitative traits using seemingly unrelated regressions.
Genetic epidemiology 2005;28(4):313-25.
2005: Patrick J Kelly; Roshini Sooriyarachchi; Nigel Stallard; Susan Todd
A practical comparison of group-sequential and adaptive designs.
Journal of biopharmaceutical statistics 2005;15(4):719-38.
2005: Patrick J Kelly; Nigel Stallard; Susan Todd
An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Journal of biopharmaceutical statistics 2005;15(4):641-58.
2004: Nigel Stallard; Lee Tombs
Including a time-of-year effect in the analysis of a matched case-control study.
Statistics in medicine 2004;23(20):3193-207.
2004: Anne Whitehead; Nigel Stallard
Opportunities for reduction in acute toxicity testing via improved design.
Alternatives to laboratory animals : ATLA 2004;32 Suppl 2():73-80.
2004: Nigel Stallard; Anne Whitehead
A statistical evaluation of the fixed dose procedure.
Alternatives to laboratory animals : ATLA 2004;32 Suppl 2():13-21.
2004: Nigel Stallard; Anne Whitehead; Ian Indans
Statistical evaluation of an acute dermal toxicity test using the dermal fixed dose procedure.
Human & experimental toxicology 2004;23(8):405-12.
2003: Nigel Stallard; Anne Whitehead; Ian Indans
Statistical evaluation of the fixed concentration procedure for acute inhalation toxicity assessment.
Human & experimental toxicology 2003;22(11):575-85.
2003: Nigel Stallard
Decision-theoretic designs for phase II clinical trials allowing for competing studies.
Biometrics 2003;59(2):402-9.
2003: Nigel Stallard; Susan Todd
Sequential designs for phase III clinical trials incorporating treatment selection.
Statistics in medicine 2003;22(5):689-703.
2002: Nigel Stallard; William F Rosenberger
Exact group-sequential designs for clinical trials with randomized play-the-winner allocation.
Statistics in medicine 2002;21(4):467-80.
2001: Nigel Stallard; P F Thall
Decision-theoretic designs for pre-phase II screening trials in oncology.
Biometrics 2001;57(4):1089-95.
2001: William F Rosenberger; Nigel Stallard; Anastasia Ivanova; C N Harper; M L Ricks
Optimal adaptive designs for binary response trials.
Biometrics 2001;57(3):909-13.
2001: Roshini Sooriyarachchi; Yinghui Zhou; Nigel Stallard; Susan Todd; Anne Whitehead
Learning from previous responses in phase I dose-escalation studies.
British journal of clinical pharmacology 2001;52(1):1-7.
2001: Nigel Stallard; Roshini Sooriyarachchi; Susan Todd; Anne Whitehead
Stopping rules for phase II studies.
British journal of clinical pharmacology 2001;51(6):523-9.
2001: Susan Todd; Anne Whitehead; Nigel Stallard; Roshini Sooriyarachchi
Interim analyses and sequential designs in phase III studies.
British journal of clinical pharmacology 2001;51(5):394-9.
2000: Nigel Stallard; Susan Todd
Exact sequential tests for single samples of discrete responses using spending functions.
Statistics in medicine 2000;19(22):3051-64.
1999: Nigel Stallard; P F Thall; Roshini Sooriyarachchi
Decision theoretic designs for phase II clinical trials with multiple outcomes.
Biometrics 1999;55(3):971-7.
1998: Nigel Stallard
Approximately optimal designs for phase II clinical studies.
Journal of biopharmaceutical statistics 1998;8(3):469-87.
1998: Nigel Stallard
Sample size determination for phase II clinical trials based on Bayesian decision theory.
Biometrics 1998;54(1):279-94.
1996: Nigel Stallard; K M Facey
Comparison of the spending function method and the Christmas tree correction for group sequential trials.
Journal of biopharmaceutical statistics 1996;6(3):361-73.
1996: Nigel Stallard; Anne Whitehead
An alternative approach to the analysis of animal carcinogenicity studies.
Regulatory toxicology and pharmacology : RTP 1996;23(3):244-8.
1995: Nigel Stallard; Anne Whitehead
The fixed-dose procedure and the acute-toxic-class method: a mathematical comparison.
Human & experimental toxicology 1995;14(12):974-90.
1995: Nigel Stallard; Anne Whitehead
Estimating the magnitude of carcinogenic effects in long-term animal studies.
Human & experimental toxicology 1995;14(8):643-53.
1995: Nigel Stallard; Anne Whitehead
Reducing animal numbers in the fixed-dose procedure.
Human & experimental toxicology 1995;14(4):315-23.
1995: R Z Omar; Nigel Stallard; J Whitehead
A parametric multistate model for the analysis of carcinogenicity experiments.
Lifetime data analysis 1995;1(4):327-46.